CASI Pharmaceuticals, a biopharmaceutical company dedicated to the acquisition, development and commercialisation of cancer therapeutics with a commercial focus on China, has appointed Rong Chen as Chief Medical Officer.
Chen brings more than 20 years of experience in the areas of pharmaceutical clinical development and regulatory affairs to the Rockville, Maryland, US-based company.
Prior to joining CASI, Chen was Area Medical Director and Chief Medical Governance Officer at GSK China/Hong Kong Area and in 2010 was promoted to VP, Head of Regulatory Centre of Excellence, Company Representative having overall responsibility for the registration of drug and vaccine products.
Before working at GSK, Chen was Medical Director, Global Medical Expert at Bayer-Schering Pharma Asia Pacific Area and from 2001–2005 was Medical Director at Sanofi China.
